● SK bioscience-Sanofi Pasteur has filed the IND amendment for Phase 2 Global Clinical Trial of Next-Generation’s Pneumococcal Conjugate Vaccine
- The IND amendment for a phase 2 study was filed last month.
- Enables access to the global pneumococcal conjugate vaccine market of USD 6.3 billion*.A next-generation’s pneumococcal conjugate vaccine (PCV) co-developed by SK bioscience with Sanofi Pasteur, a global leader in the vaccine industry, is on the doorstep of phase 2 clinical evaluation.
On 30th March, 2020, SK bioscience(CEO Jaeyong Ahn) announced that an IND amendment for a phase 2 clinical trial with the Next-Generation’s PCV was filed last month in the United States with plans for the trial to be initiated following regulatory review.
In 2014, SK chemicals signed an agreement with Sanofi Pasteur to co-develop and commercialize an innovative vaccine against pneumococcal infection.In the end of 2019, a non-refundable $11 Million milestone payment was received by SK bioscience upon successful completion of a Phase I study.
The global pneumococcal conjugate vaccine market reached the size of USD 6.3 billion in 2017. This market is expected to grow to the size of USD 9 billion by 2025 (Source: Allied Market Research, published on May, 2019).
“The goal to develop and commercialize enormous patient value in global market is being realized step by step based on SK’s technology” remarked Jaeyong Ahn, the CEO of SK bioscience. Ahn also emphasized that SK bioscience is “determined to overcome challenges ahead by delivering its ceaseless efforts to achieve this invaluable goal.”
Meanwhile, SK bioscience, carved-out from SK chemicals in 2018, is a South Korean biopharma company specialized in vaccine business. Particularly, the company has successfully obtained the WHO prequalification of trivalent and quadrivalent cell culture-based influenza vaccines, and varicella vaccines which allows the access to the international public market. On February 12, 2018, SK chemicals and Sanofi Pasteur announced a license agreement for cell culture technology for potential use for influenza vaccine.
# Photo : L-house, SK bioscience in Andong